Skip to content
StockMarketAgent
Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CAI stock hub

Caris Life Sciences, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

CAIis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
4.6B
NASDAQ
Market data

Live price

Current market quote for this ticker.

Current price
CAI
In the news

Latest news · CAI

Recent company headlines from major financial publishers.

Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E85.7
P25 12.6P50 18.3P75 33.7
Trailing P/En/a
P25 15P50 23.3P75 38.5
ROE28.4
P25 -106.6P50 -46.9P75 -3.1
ROIC12.5
P25 -63.1P50 -27.5P75 -0
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All CAI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
211
Groups with data
11
Currency
USD
Showing 211 of 211 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

25
MetricValue
Cik
0002019410
Company name
Caris Life Sciences, Inc.
Country
United States
Country code
US
Cusip
142152107
Employees
1,846
Employees Change
77%
Employees Change Percent
4.35
Enterprise value
$4.2B
Exchange
NASDAQ
Financial currency
USD
First seen
2026-05-09
Industry
Biotechnology
IPO Date
2025-06-18
Isin
US1421521071
Last refreshed
2026-05-10
Market cap
$4.6B
Market cap category
Mid-Cap
Price
$16.15
Price currency
USD
Rev Per Employee
491,490.79x
Sector
Healthcare
Sic
8071
Symbol
CAI
Website
https://www.carislifesciences.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

11
MetricValue
Earnings Yield
-9.01%
EV Sales Forward
3.85x
EV/EBIT
38.46x
EV/EBITDA
32.3x
EV/FCF
33.75x
EV/Sales
4.59x
FCF yield
2.7%
Forward P/E
85.68x
P/B ratio
7.69x
P/S ratio
5.03x
PS Forward
4.22x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

17
MetricValue
EBIT Margin
11.94%
EBITDA Margin
14.22%
FCF margin
13.61%
Gross margin
68.92%
Gross Profit
$625.3M
Gross Profit Growth
195.83%
Gross Profit Growth Q
147.71%
Net Income
$-411.4M
Net Income Growth Quarters
3%
Net Income Growth Years
0%
Pretax Margin
3.73%
Profit Margin
3.75%
Profit Per Employee
$-222,873
ROA
9.31
ROCE
10.64
ROE
28.35
ROIC
12.49

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

5
MetricValue
EPS Growth Years
2
Revenue Growth
100.51x
Revenue Growth Q
78.78x
Revenue Growth Quarters
5x
Revenue Growth Years
2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

21
MetricValue
Asset Turnover
$1.25
Assets
$1.2B
Cash
$823.5M
Current Assets
$1B
Current Liabilities
$143.9M
Debt
$425.2M
Debt EBITDA
$3.04
Debt Equity
$0.72
Debt FCF
$3.44
Equity
$593.5M
Interest Coverage
1.9
Liabilities
$568.9M
Long Term Assets
$148.2M
Long Term Liabilities
$425M
Net Cash
$398.3M
Net Cash By Market Cap
$8.72
Net Debt EBITDA
$-3.09
Net Debt Equity
$-0.67
Net Debt FCF
$-3.23
Tangible Book Value
$574.1M
Tangible Book Value Per Share
$2.03

Liquidity

Current-asset coverage and working-capital efficiency metrics.

6
MetricValue
Current ratio
7.05
Inventory Turnover
5
Net Working Capital
$47M
Quick ratio
6.35
Working Capital
$870.3M
Working Capital Turnover
$2.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

2
MetricValue
Buyback Yield
-543.56%
Dividend Yield
0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

35
MetricValue
200-day SMA
26.25
50-day SMA
19.08
50-day SMA vs 200-day SMA
50under200
All Time High
42.5
All Time High Change
-62%
All Time High Date
2025-08-22
All Time Low
15.71
All Time Low Change
2.8%
All Time Low Date
2026-05-08
ATR
1.29
Beta1y
1.85
Ch YTD
-40.14
High
17.39
High52
42.5
High52 Date
2025-08-22
High52ch
-62%
Low
15.71
Low52
15.71
Low52 Date
2026-05-08
Low52ch
2.8%
Ma50ch
-15.35%
Premarket Change Percent
-14.57
Premarket Price
$16.95
Premarket Volume
30,624
Price vs 200-day SMA
-38.47%
RSI
35.74
RSI Monthly
0
RSI Weekly
36.03
Sharpe ratio
-0.77x
Sortino ratio
-0.93
Total Return
-543.56%
Tr YTD
-40.14
Tr1m
-13.87%
Tr1w
-12.56%
Tr3m
-26.59%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

13
MetricValue
Analyst Count
12
Analyst Count Top
2
Analyst Price Target Top
$24.5
Analyst Ratings
Strong Buy
Analyst Ratings Top
Buy
Earnings EPS Estimate
$-0.02
Earnings Revenue Estimate
209,494,568x
Earnings Revenue Estimate Growth
73.26x
Operating Income
$108.3M
Operating margin
11.94
Price target
$29.17
Price Target Change
$80.62
Price Target Change Top
$51.7

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

11
MetricValue
Float
96,539,546%
Float Percent
34.15%
Net Borrowing
27,741,000
Shares Insiders
48.36%
Shares Institutions
44.1%
Shares Out
282,662,545
Shares Qo Q
-4.57%
Shares Yo Y
543.56%
Short Float
12.21%
Short Ratio
4.48
Short Shares
4.17

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

65
MetricValue
Adjusted FCF
$52.3M
Average Volume
2,130,444.1x
Bv Per Share
2.1
CAPEX
$-23.9M
Ch1m
-13.87
Ch1w
-12.56
Ch3m
-26.59
Ch6m
-36.94
Change
-18.6%
Change From Open
-3.87
Close
19.84
Days Gap
-15.32
Depreciation Amortization
20,635,000
Dollar Volume
143,322,141.4
Earnings Date
2026-05-07
Earnings Time
amc
EBIT
$108.3M
EBITDA
$129M
EPS
$-1.8
F Score
5
FCF
$123.5M
FCF EV Yield
2.96x
FCF Per Share
$0.44
Financing CF
664,528,000
Fiscal Year End
December
Founded
2,008
Goodwill
19,344,000
Income Tax
$-134,000
Investing CF
-23,913,000
Ipr
-23.1
Iprfo
-40.19
Is Primary Listing
1
Is Spac
No
Last Earnings Date
2026-05-07
Last Report Date
2026-03-31
Last Split Type
Never
Last10k Filing Date
2026-03-03
Ma150
24
Ma150ch
-32.7%
Ma20
19.54
Ma20ch
-17.34%
Net CF
788,100,000
Next Earnings Date
2026-08-11
Open
16.8
Optionable
Yes
P FCF Ratio
36.98
P OCF Ratio
30.98
Position In Range
26.19
Post Close
16.15
Postmarket Change Percent
0.25
Postmarket Price
$16.19
Ppne
82,669,000
Pre Close
19.84
Price Date
2026-05-08
Price EBITDA
$35.39
Ptbv Ratio
7.95
Relative Volume
4.17x
Revenue
907,292,000x
SBC By Revenue
7.85x
Share Based Comp
71,187,000
Tax By Revenue
-0.01x
Tr6m
-36.94%
Us State
Texas
Volume
8,874,436
Z Score
7.03
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does CAI pay a dividend?

Capital-return profile for this ticker.

Ownership

Who owns CAI?

Insider, institutional, and short-interest positioning.

Institutional ownership
+44.1%
Float: +34.2% of shares outstanding
Insider ownership
+48.4%
Stake held by company insiders. Higher generally signals alignment.
Short interest
+12.2%
4.5 days to cover
Y/Y dilution
+543.6%
Negative means the company is buying back shares.
Technical

CAI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
35.7
Neutral momentum band
Price vs 200-day MA
-38.5%
50/200-day relationship not available
Beta (5Y)
n/a
Sensitivity to the broader market
Sharpe ratio
-0.77
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About CAI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CAI stock rating?

Caris Life Sciences, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CAI analysis?

The full report lives at /stocks/CAI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CAI?

The latest report frames CAI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CAI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.